Growth Hormone: The Expansion of Available Products and Indications

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 3, 2009, Pages 587-611

  Franklin, Sherry L ^a   Geffner, Mitchell E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Growth hormone; Indications; ISS; Prader Willi syndrome; SHOX; Small for gestational age; Turner syndrome

Indexed keywords

ACCRETROPIN; ANSOMONE; ARGININE; CLONIDINE; CORTICOTROPIN; FITROPIN; GLUCAGON; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HUMAN GROWTH HORMONE; HYPERTROPIN; INSULIN; JANUS KINASE; LEVODOPA; OXANDROLONE; PROPRANOLOL; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATREM; STAT PROTEIN; TEVTROPIN; UNCLASSIFIED DRUG;

ANENCEPHALUS; ARTHRALGIA; BRAIN PSEUDOTUMOR; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGENITAL BLOOD VESSEL MALFORMATION; CRANIOPHARYNGIOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; ENCEPHALITIS; EPIPHYSIOLYSIS; FOOD AND DRUG ADMINISTRATION; GLIOMA; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HEAD INJURY; HEMOCHROMATOSIS; HEMODIALYSIS; HISTIOCYTOSIS X; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSITIS; INDIVIDUALIZATION; INJECTION SITE REACTION; INSULIN TOLERANCE TEST; KIDNEY TRANSPLANTATION; MENINGITIS; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOONAN SYNDROME; OPTIC NERVE HYPOPLASIA; PATHOPHYSIOLOGY; PATIENT CARE; PERIPHERAL EDEMA; PERITONEAL DIALYSIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROVOCATION TEST; RADIOTHERAPY; RATHKE CLEFT CYST; RECOMMENDED DRUG DOSE; REVIEW; SARCOIDOSIS; SEPTOOPTIC DYSPLASIA; SHORT BOWEL SYNDROME; SHORT STATURE; SKULL DEFECT; SMALL FOR DATE INFANT; SOCIAL ISOLATION; SURGICAL TECHNIQUE; TURNER SYNDROME; UNITED STATES; WASTING SYNDROME;

GROWTH DISORDERS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMAN GROWTH HORMONE; HUMANS; PRADER-WILLI SYNDROME; TURNER SYNDROME;

EID: 69249136612     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.06.006     Document Type: Review

References (92)

1. McKusick V.A., and Rimoin D.L. General Thom Thumb and other midgits. Sci Am 217 (1967) 102-106
2. Raben M.S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18 (1958) 901-903
3. Frasier S.D. The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr 131 (1997) S1-S4
4. Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society. Degenerative neurologic disease in patients formerly treated with human growth hormone. J Pediatr 107 (1985) 10-12
5. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl 325 (1986) 1-9
6. Cronin M.J. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. J Pediatr 131 (1997) S5-S7
7. Massa G., Vanderschueren-Lodeweyckx M., and Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone-deficient children treated with recombinant human growth hormone. Clin Endocrinol 38 (1993) 137-142
8. Takahashi Y., Kaji H., Okimura Y., et al. Short stature caused by a mutant growth hormone. N Engl J Med 334 (1996) 432-436
9. Dattani M.T. Novel insights into the aetiology and pathogenesis of hypopituitarism. Horm Res 62 Suppl 3 (2004) 1-13
10. Traggiai C., and Stanhope R. Endocrinopathies associated with midline cerebral and cranial malformations. J Pediatr 140 (2002) 252-255
11. Costin G. Endocrine disorders associated with tumors of the pituitary and hypothalamus. Pediatr Clin North Am 26 (1979) 15-31
12. Mayfield R.K., Levine J.H., Gordon L., et al. Lymphoid adenohypophysitis presenting as a pituitary tumor. Am J Med 69 (1980) 619-623
13. Bartsocas C.S., and Pantelakis S.N. Human growth hormone therapy in hypopituitarism due to tuberculous meningitis. Acta Paediatr Scand 62 (1973) 304-306
14. Stuart C.A., Neelon F.A., and Lebovitz H.E. Hypothalamic insufficiency: the cause of hypopituitarism in sarcoidosis. Ann Intern Med 88 (1978) 589-594
15. Donadieu J., Rolon M.A., Pion I., et al., French LCH Study Group. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab 89 (2004) 604-609
16. Lewis A.S., Courtney C.H., and Atkinson A.B. All patients with idiopathic hypopituitarism should be screened for hemochromatosis. Pituitary 12 (2008) 273-275
17. Aimaretti G., Ambrosio M.R., Benvenga S., et al. Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Horm IGF Res 14 Suppl A (2004) S114-S117
18. Darzy K.H., and Shalet S.M. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Horm IGF Res 16 Suppl A (2006) S30-S40
19. Roman J., Villaizan C.J., Garcia-Foncillas J., et al. Growth and growth hormone secretion in children with cancer treated with chemotherapy. J Pediatr 131 (1997) 105-112
20. Blizzard R.M., and Bulatovic A. Psychosocial short stature: a syndrome with many variables. Baillieres Clin Endocrinol Metab 6 (1992) 687-712
21. Pandian R., and Nakamoto J.M. Rational use of the laboratory for childhood and adult growth hormone deficiency. Clin Lab Med 24 (2004) 141-174
22. Gale E.A., Bennett T., MacDonald I.A., et al. The physiological effects of insulin-induced hypoglycaemia in man: responses at differing levels of blood glucose. Clin Sci 65 (1983) 263-271
23. Shah A., Stanhope R., and Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. Br Med J 304 (1992) 173-174
24. Frasier S.D. A review of growth hormone stimulation tests in children. Pediatrics 53 (1974) 929-937
25. Bonfig W., Bechtold S., Bachmann S., et al. Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab 21 (2008) 1049-1056
26. Rosenfeld R.G. Evaluation of growth and maturation in adolescence. Pediatr Rev 4 (1982) 175-183
27. Ranke M.B., Schweizer R., Wollmann H.A., et al. Dosing of growth hormone in growth hormone deficiency. Horm Res 51 Suppl 3 (1999) 70-74
28. Cutfield W., Lindberg A., Albertsson Wikland K., et al. Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta Paediatr Suppl 88 (1999) 72-75
29. Wetterau L., and Cohen P. Role of insulin-like growth factor monitoring in optimizing growth hormone therapy. J Pediatr Endocrinol Metab 13 Suppl 6 (2000) 1371-1376
30. Zucchini S., Pirazzoli P., Baronio F., et al. Effects on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab 91 (2006) 4271-4276
31. Giovannuci E., and Pollak M. Risk of the cancer after growth hormone treatment. Lancet 360 (2002) 258-259
32. Sklar C.A. Growth hormone treatment: cancer risk. Horm Res 62 (2004) 30-34
33. Seikaly M.G., Salhab N., Gipson D., et al. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol 21 (2006) 793-799
34. Johannsson G., and Ahlmen J. End-stage renal disease: endocrine aspects of treatment. Growth Horm IGF Res 11 (2001) 59-71
35. Mehls O., Wuhl E., Tonsshoff B., et al. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr 97 (2008) 1159-1164
36. Roelfsema V., and Clark R.G. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12 (2001) 1297-1306
37. Tonshoff B., Cronin M.J., Reichert M., et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab 82 (1997) 1007-1013
38. Rabkin R., Sun D.F., Chen Y., et al. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20 (2005) 313-318
39. Nissel R., Lindberg A., Mehls O., et al. Pfizer International Growth Database (KIGS) International Board. Factors predicting the near final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab 93 (2008) 1359-1365
40. Wuhl E., and Schaefer F. Effects of growth hormone in patients with chronic renal failure: experience in children and adults. Horm Res 58 Suppl 3 (2002) 35-38
41. Doi T., Striker L.J., Quaife C., et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone-releasing factor but not in those expressing insulin-like growth factor-1. Am J Pathol 131 (1988) 398-403
42. Fine R.N., Sullivan E.K., Kuntze J., et al. The impact of recombinant human growth hormone treatment during chronic renal insufficiency on renal transplant recipients. J Pediatr 136 (2000) 376-382
43. Guest G., Berard E., Crosnier H., et al. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr Nephrol 12 (1998) 437-446
44. Cutfield W.S., Wilton P., Bennmarker H., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 355 (2000) 610-613
45. Ranke M.B., Pfluger H., Rosendahl W., et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 141 (1983) 81-88
46. Rao E., Weiss B., Fukami M., et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16 (1997) 54-63
47. Davenport ML, Quigley CA, Bryant CG, et al. Effect of early growth hormone (GH) treatment in very young girls with Turner syndrome (TS). Presented at the Seventh Joint European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society Meeting. Lyon, France, September 23, 2005.
48. Rosenfeld R.G., Attie K.M., Frane J., et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 132 (1998) 319-324
49. Bolar K., Hoffman A.R., Maneatis T., et al. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab 93 (2008) 344-351
50. Munce T., Simpson R., and Bowling F. Molecular characterization of Prader-Willi syndrome by real-time PCR. Genet Test 12 (2008) 319-324
51. Tauber M. Effects of growth hormone treatment in children presenting with Prader-Willi syndrome: the KIGS experience. In: Ranke M.B., Price D.A., and Reiter E.O. (Eds). Growth hormone therapy in Pediatrics-20 years of KIGS (2007), Karger, Basel 377-387
52. Wollmann H.A., Schultz U., Grauer M.L., et al. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediatr 157 (1998) 634-642
53. Corrias A., Bellone J., Beccaria L., et al. IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 23 (2000) 84-89
54. Eiholzer U., Bachmann S., and I'Allemand D. Is there growth hormone deficiency in Prader-Willi syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader-Willi syndrome. Horm Res 53 Suppl 3 (2000) 44-52
55. Carrel A.L., Myers S.E., Whitman B.Y., et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 87 (2002) 1581-1585
56. Angulo M.A., Castro-Magana M., Lamerson M., et al. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A 143 (2007) 1456-1461
57. Whitman B.Y., Myers S., Carrel A., et al. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Pediatrics 109 (2002) E35
58. Festen D.A.M., Wevers M., Lindgren A.C., et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 68 (2008) 919-925
59. Festen D.A., Visser T.J., Otten B.J., et al. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment. Clin Endocrinol (Oxf) 67 (2007) 449-456
60. Tauber M., Diene G., Molinas C., et al. A review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A 46 (2008) 881-887
61. Mogul H.R., Lee P.D., Whitman B.Y., et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab 93 (2008) 1238-1245
62. Hokken-Koelega A.C., De Ridder M.A., Lemmen R.J., et al. Children born small for gestational age: do they catch up?. Pediatr Res 38 (1995) 267-271
63. Lee P.A., Chernausek S.D., and Hokken-Koelega A.C. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics 111 (2003) 1253-1261
64. Sas T., Mulder P., Aanstoot H.J., et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 54 (2001) 243-251
65. Ranke M.B. Towards a consensus on the definition of idiopathic short stature. Horm Res 45 Suppl 2 (1996) 64-66
66. Cohen P., Rogol A.D., Deal C.L., et al., 2007 Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 93 (2008) 4210-4217
67. Rochiccioli P., Battin J., Bertrand A.M., et al. Final height in Turner syndrome patients treated with growth hormone. Horm Res 44 (1995) 172-176
68. Cohen P., Rogol A.D., Howard C.P., et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 92 (2007) 2480-2486
69. Belin V., Cusin V., Viot G., et al. SHOX mutations in dyschondrosteosis (Léri-Weill syndrome). Nat Genet 19 (1998) 67-69
70. Huber C., Rosilio M., Munnich A., et al., French SHOX GeNeSIS Module. High incidence of SHOX anomalies in patients with short stature. J Med Genet 43 (2006) 735-739
71. Blum W.F., Crowe B.J., Quigley C.A., et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: two-year results of a randomized, controlled multicenter trial. J Clin Endocrinol Metab 92 (2007) 219-228
72. Tartaglia M., Mehler E.L., Goldberg R., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29 (2001) 465-468
73. Stofega M.R., Herrington J., Billestrup N., et al. Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 14 (2000) 1338-1350
74. 3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocrinology 143 (2002) 4259-4264
75. Ferreira L.V., Souza S.A., Arnhold I.J., et al. PTPN11 mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90 (2005) 5156-5160
76. Limal J.M., Parfait B., Cabrol S., et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 91 (2006) 300-306
77. Cotterill A.M., McKenna W.J., Brady A.F., et al. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. J Clin Endocrinol Metab 81 (1996) 2291-2297
78. Molitch M.E., Clemmons D.R., Malozowski S., et al. Endocrine Society's Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91 (2006) 1621-1634
79. Laursen T., Jørgensen J.O., and Christiansen J.S. The management of adult growth hormone deficiency syndrome. Expert Opin Pharmacother 9 (2008) 2435-2450
80. Biller B.M., Samuels M.H., Zagar A., et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87 (2002) 2067-2079
81. Mulligan K., and Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 85 (2002) 151-159
82. Morley J.E., Thomas D.R., and Wilson M.M. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83 (2006) 735-743
83. Heijligenberg R., Sauerwein H.P., Brabant G., et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 81 (1996) 4028-4032
84. Geffner M.E., Yeh D.Y., Landaw E.M., et al. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 34 (1993) 66-72
85. Schambelan M., Mulligan K., Grunfeld C., et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 125 (1996) 873-882
86. Gelato M., McNurlan M., and Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 29 (2007) 2269-2288
87. Macallan D.C., Baldwin C., Mandalia S., et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 9 (2008) 254-268
88. Lund P.K., Ulshen M.H., Rountree D.B., et al. Molecular biology of gastrointestinal peptides and growth factors: relevance to intestinal adaptation. Digestion 46 Suppl 2 (1990) 66-73
89. Guarino A., De Marco G., and Italian National Network for Pediatric Intestinal Failure. Natural history of intestinal failure, investigated through a national network-based approach. J Pediatr Gastroenterol Nutr 37 (2003) 136-141
90. Pereira P.M., and Bines J.E. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome. J Gastroenterol Hepatol 21 (2006) 932-940
91. Messing B., Blethen S., Dibaise J.K., et al. Treatment of adult short bowel syndrome with recombinant human growth hormone: a review of clinical studies. J Clin Gastroenterol 40 Suppl 2 (2006) S75-S84
92. Weiming Z., Ning L., and Jieshou L. Effect of recombinant human growth hormone and enteral nutrition on short bowel syndrome. JPEN J Parenter Enteral Nutr 28 (2004) 377-381